These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19815659)

  • 1. Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods.
    Stollenwerk B; Stock S; Siebert U; Lauterbach KW; Holle R
    Med Decis Making; 2010; 30(3):304-13. PubMed ID: 19815659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
    Brisson M; Edmunds WJ
    Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.
    Stevenson MD; Oakley J; Chilcott JB
    Med Decis Making; 2004; 24(1):89-100. PubMed ID: 15005958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
    Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
    Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
    [No Abstract]   [Full Text] [Related]  

  • 7. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems of using modelling in the economic evaluation of health care.
    Sheldon TA
    Health Econ; 1996; 5(1):1-11. PubMed ID: 8653188
    [No Abstract]   [Full Text] [Related]  

  • 10. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods.
    Groot Koerkamp B; Myriam Hunink MG; Stijnen T; Weinstein MC
    Health Econ; 2006 Apr; 15(4):383-92. PubMed ID: 16389669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group].
    Med Klin (Munich); 2000 Jan; 95(1):52-5. PubMed ID: 10668346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Decisions in case of "problematic" cost-effectiveness ratios based on the example of a clinical trial in rehabilitation care].
    Leidl R; Jacobi E; Knab J; Schweikert B
    Gesundheitswesen; 2006 Apr; 68(4):249-56. PubMed ID: 16705561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Handling uncertainty when performing economic evaluation of healthcare interventions.
    Briggs AH; Gray AM
    Health Technol Assess; 1999; 3(2):1-134. PubMed ID: 10448202
    [No Abstract]   [Full Text] [Related]  

  • 14. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation using mathematical models: the case of misoprostol prophylaxis.
    Gabriel SE
    J Rheumatol; 1995 Jul; 22(7):1412-4. PubMed ID: 7562787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.
    Kilian R; Matschinger H; Löeffler W; Roick C; Angermeyer MC
    J Ment Health Policy Econ; 2002 Mar; 5(1):21-31. PubMed ID: 12529567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problems in interpreting cost effectiveness in clinical trials. Experimental versus implementation costs.
    De Nino LA; Mulrow CD; Gerety MB; Averyt EC
    Online J Curr Clin Trials; 1993 Apr; Doc No 44():[4864 words; 42 paragraphs]. PubMed ID: 8306003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study.
    Rogowski WH
    Med Decis Making; 2009; 29(2):224-38. PubMed ID: 19182214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inexpensive health care reform: the mathematics of medicine.
    Forsyth RA
    Med Hypotheses; 2010 Feb; 74(2):387-8. PubMed ID: 19775823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
    Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
    J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.